Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes

被引:150
|
作者
Petroff, MGV
Egan, JM
Wang, XL
Sollott, SJ
机构
[1] NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, Intramural Res Program,NIH, Baltimore, MD 21224 USA
[2] NIA, Diabet Sect, Gerontol Res Ctr, Intramural Res Program,NIH, Baltimore, MD 21224 USA
[3] Univ Nacl La Plata, Fac Ciencias Med, Ctr Invest Cardiovasc, La Plata, Buenos Aires, Argentina
关键词
cardiac myocytes; glucagon-like peptide-1; cAMP; calcium;
D O I
10.1161/hh1701.095716
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The gut hormone, glucagon-like peptide-1 (GLP-1), which is secreted in nanomolar amounts in response to nutrients in the intestinal lumen, exerts cAMP/protein kinase A-mediated insulinotropic actions in target endocrine tissues, but its actions in heart cells are unknown. GLP-1 (10 nmol/L) increased intracellular cAMP (from 5.7+/-0.5 to 13.1 +/- 0.12 pmol/mg protein) in rat cardiac myocytes. The effects of cAMP-doubling concentrations of both GLP-1 and isoproterenol (ISO. 10 nmol/L) on contraction amplitude, intracellular Ca2+ transient (CaT), and pH(i) in indo-1 and seminaphthorhodafluor (SNARF)-1 loaded myocytes were compared. Whereas ISO caused a characteristic increase (above baseline) in contraction amplitude (160+/-34%) and CaT (70+/-5%), GLP-1 induced a significant decrease in contraction amplitude (-27+/-5%) with no change in the CaT after 20 minutes. Neither pertussis toxin treatment nor exposure to the cGMP-stimulated phosphodiesterase (PDE2) inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine or the nonselective PDE inhibitor 3-isobutyl-1-methylxanthine nor the phosphatase inhibitors okadaic acid or calyculin A unmasked an ISO-mimicking response of GLP-1. In SNARF-1-loaded myocytes, however, both ISO and GLP-1 caused an intracellular acidosis (Delta pH(i) -0.09+/-0.02 and -0.08+/-0.03, respectively). The specific GLP-1 antagonist exendin 9-39 and the cAMP inhibitory analog Rp-8CPT-cAMPS inhibited both the GLP-1-induced intracellular acidosis and the negative contractile effect. We conclude that in contrast to beta -adrenergic signaling, GLP-1 increases cAMP but fails to augment contraction, suggesting the existence of functionally distinct adenylyl cyclase/cAMP/protein kinase A compartments, possibly determined by unique receptor signaling microdomains that are not controlled by pertussis toxin-sensitive G proteins or by enhanced local PDE or phosphatase activation. Furthermore, GLP-1 elicits a cAMP-dependent modest negative inotropic effect produced by a decrease in myofilament-Ca2+ responsiveness probably resulting from intracellular acidification.
引用
收藏
页码:445 / 452
页数:8
相关论文
共 50 条
  • [41] GLUCAGON-LIKE PEPTIDE-1 BINDING TO RAT SKELETAL-MUSCLE
    DELGADO, E
    LUQUE, MA
    ALCANTARA, A
    TRAPOTE, MA
    CLEMENTE, F
    GALERA, C
    VALVERDE, I
    VILLANUEVAPENACARRILLO, ML
    PEPTIDES, 1995, 16 (02) : 225 - 229
  • [42] Glucagon-like peptide-1 secretion from proximal rat intestine
    Svendsen, B.
    Pedersen, J.
    Holst, J. J.
    DIABETOLOGIA, 2011, 54 : S211 - S211
  • [43] Characterization of Heart Rate Increases With Glucagon-Like Peptide-1 Agonist Therapy
    Chilton, Robert J.
    MacConell, Leigh A.
    Han, Jenny C.
    Marso, Steven P.
    CIRCULATION, 2013, 128 (22)
  • [44] Differentiation of glucagon and glucagon-like peptide-1 effects on hepatocytes
    Wang, Xiaozhen
    Conway, James
    Beaton, Michelle
    De Los Reyes, Melissa
    Raja, Rajiv
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E552 - E552
  • [45] Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
    Kang, Mi Yeon
    Oh, Tae Jung
    Cho, Young Min
    ENDOCRINOLOGY AND METABOLISM, 2015, 30 (02) : 216 - 220
  • [46] The effect of glucagon-like peptide-1 and glucagon-like peptide-2 on microcirculation: A systematic review
    Nerup, Nikolaj
    Ambrus, Rikard
    Lindhe, Joanna
    Achiam, Michael P.
    Jeppesen, Palle B.
    Svendsen, Lars B.
    MICROCIRCULATION, 2019, 26 (03)
  • [47] Can epicardial fat glucagon-like peptide-1 receptor open up to the cardiovascular benefits of glucagon-like peptide-1 analogues?
    Iacobellis, Gianluca
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (03): : 224 - 225
  • [48] Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism
    Hansen, Morten S. S.
    Tencerova, Michaela
    Frolich, Jacob
    Kassem, Moustapha
    Frost, Morten
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (01) : 25 - 37
  • [49] Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
    Vishnoi, Shubham
    Bhattacharya, Shayon
    Walsh, Erica M.
    Okoh, Grace Ilevbare
    Thompson, Damien
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2023, 63 (15) : 4934 - 4947
  • [50] Role of glucagon-like peptide-1 in cardiac remodelling after myocardial infarction
    Cassidy, R. S.
    Green, B. D.
    Grieve, D. J.
    HEART, 2008, 94 (09)